Enfortumab Vedotin, an ADC directed against NECTIN-4, demonstrated activity in R/M HNSCC in a single arm phase II trial in 46 platinum and immunotherapy pre-treated HNSCC patients (including 10 LSCC patients). The gene discussed is NECTIN4; the disease is head and neck squamous cell carcinoma.